StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued on Saturday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of NYSE OGEN opened at $0.33 on Friday. The stock has a market cap of $1.82 million, a PE ratio of -0.04 and a beta of 0.45. The business has a fifty day moving average of $0.72 and a two-hundred day moving average of $1.15. Oragenics has a 52-week low of $0.29 and a 52-week high of $7.74.

Oragenics (NYSE:OGEN) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC acquired a new stake in Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.